EUVIMEDEUVIMED entdecken
Crossref

Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry

Shankha Dey, Rushikesh Biradar, Sayalee Sanjay Mane, Anandhu Kunnath Shaji, Agneesh Pratim Das, Subhash Mohan Agarwal, Swapnil Jayant Dengale

Journal of Pharmaceutical and Biomedical Analysis · 2024

DOI: 10.1016/j.jpba.2024.116116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2024. Verfasst von Shankha Dey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, India. Hauptthemen laut MEDLINE: Epoxide Hydrolases, Rats, Wistar, Tandem Mass Spectrometry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EC5026 is a novel soluble epoxide hydrolase inhibitor being developed clinically to treat neuropathic pain and inflammation. In the current study, we employed the LC-ESI-Q-TOF-MS/MS technique to identify four in-vivo phase-I metabolites of EC5026 in rat model, out of which three were found to be novel. The identified metabolites include aliphatic hydroxylation, di-hydroxylation, terminal desaturation, and carboxylation. No phase-II metabolites were found. The pharmacokinetic profile of identified metabolites was established after a single oral dose of EC5026 to Wistar rats. The Tmax of the drug and metabolites were found to be in the range of 1-2 hours and 4-12 hours, respectively. The major metabolites M1 and M2 were found to have more than 2-fold (263.87% AUC) and equivalent exposure (96.33% AUC) compared to the parent drug, respectively. Further, the docking study revealed that the mono-hydroxylated and terminally desaturated metabolites possess better binding affinity than the parent drug. Therefore, these metabolites may hold sEH inhibition potential and can be followed through future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epoxide HydrolasesRats, WistarTandem Mass SpectrometryAnimalsRatsMaleEnzyme InhibitorsChromatography, LiquidHydroxylationAdministration, OralSpectrometry, Mass, Electrospray Ionization

Stichwörter der Autor:innen

EC5026LC-ESI-QTOF-MS/MSMetabolitesMolecular dockingPharmacokinetics

Substanzen

Epoxide HydrolasesEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, India.
  • ICMR-National Institute of Cancer Prevention and Research, I-7, Sector-39, Noida 201301, India.
  • Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, India. Electronic address: swapnil@niperguwahati.in.

Zitieren

APA

Dey, S., Biradar, R., Mane, S. S., Kunnath Shaji, A., Das, A. P., Agarwal, S. M., & Dengale, S. J. (2024). Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116116

Vancouver

Dey S, Biradar R, Mane SS, Kunnath Shaji A, Das AP, Agarwal SM, et al. Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2024. doi:10.1016/j.jpba.2024.116116

BibTeX
@article{Dey2024,
  author = {Dey, Shankha and Biradar, Rushikesh and Mane, Sayalee Sanjay and Kunnath Shaji, Anandhu and Das, Agneesh Pratim and Agarwal, Subhash Mohan and Dengale, Swapnil Jayant},
  title = {Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry},
  journal = {Journal of Pharmaceutical and Biomedical Analysis},
  year = {2024},
  doi = {10.1016/j.jpba.2024.116116}
}
Kostenlos starten →